822 related articles for article (PubMed ID: 1330300)
1. T cell recognition of Epstein-Barr virus associated lymphomas.
Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.
Hamilton-Dutoit SJ; Rea D; Raphael M; Sandvej K; Delecluse HJ; Gisselbrecht C; Marelle L; van Krieken HJ; Pallesen G
Am J Pathol; 1993 Oct; 143(4):1072-85. PubMed ID: 8214003
[TBL] [Abstract][Full Text] [Related]
3. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
[TBL] [Abstract][Full Text] [Related]
5. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2.
Khanna R; Burrows SR; Suhrbier A; Jacob CA; Griffin H; Misko IS; Sculley TB; Rowe M; Rickinson AB; Moss DJ
J Immunol; 1993 Jun; 150(11):5154-62. PubMed ID: 7684421
[TBL] [Abstract][Full Text] [Related]
6. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus infection and associated products (LMP, EBNA2, vIL-10) in nodal non-Hodgkin's lymphoma of human immunodeficiency virus-negative Japanese.
Ohshima K; Suzumiya J; Tasiro K; Mukai Y; Tanaka T; Kato A; Kikuchi M
Am J Hematol; 1996 May; 52(1):21-8. PubMed ID: 8638607
[TBL] [Abstract][Full Text] [Related]
8. Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition.
Griffin H; Rowe M; Murray R; Brooks J; Rickinson A
Eur J Immunol; 1992 Jul; 22(7):1741-8. PubMed ID: 1378014
[TBL] [Abstract][Full Text] [Related]
9. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
Blaschke S; Hannig H; Buske C; Kaup FJ; Hunsmann G; Bodemer W
J Med Virol; 2001 Sep; 65(1):114-20. PubMed ID: 11505452
[TBL] [Abstract][Full Text] [Related]
10. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
Gregory CD; Rowe M; Rickinson AB
J Gen Virol; 1990 Jul; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
[TBL] [Abstract][Full Text] [Related]
11. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1.
Kis LL; Takahara M; Nagy N; Klein G; Klein E
Immunol Lett; 2006 Apr; 104(1-2):83-8. PubMed ID: 16386314
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus (EBV) latent membrane protein 1 increases HLA class II expression in an EBV-negative B cell line.
Zhang Q; Brooks L; Busson P; Wang F; Charron D; Kieff E; Rickinson AB; Tursz T
Eur J Immunol; 1994 Jun; 24(6):1467-70. PubMed ID: 8206105
[TBL] [Abstract][Full Text] [Related]
13. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus, lymphomas and Hodgkin's disease.
Young LS; Rowe M
Semin Cancer Biol; 1992 Oct; 3(5):273-84. PubMed ID: 1335791
[TBL] [Abstract][Full Text] [Related]
15. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
16. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
Callahan J; Pai S; Cotter M; Robertson ES
Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
[TBL] [Abstract][Full Text] [Related]
17. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis.
Gregory CD; Dive C; Henderson S; Smith CA; Williams GT; Gordon J; Rickinson AB
Nature; 1991 Feb; 349(6310):612-4. PubMed ID: 1705663
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]